Dr. Aragon-Ching on the Future Implications of the JAVELIN Bladder 100 Trial in Urothelial Cancer

Jeanny B. Aragon-Ching, MD, FACP, clinical program director, Genitourinary Cancers, the Inova Schar Cancer Institute, discusses the future implications of the phase 3 JAVELIN Bladder 100 (NCT02603432) trial in urothelial cancer.

JAVELIN Bladder 100 evaluated avelumab (Bavencio) maintenance plus best supportive care vs best supportive care alone in patients with locally advanced or metastatic urothelial carcinoma who did not progress following first-line, platinum-based chemotherapy.

Although avelumab maintenance generated responses during the trial, the majority of patients still experienced disease progression, Aragon-Ching explains. Building upon avelumab maintenance to improve rates and duration of response remains an unmet need in the treatment of patients with locally advanced or metastatic urothelial carcinoma, Aragon-Ching adds.

Ongoing clinical trials are evaluating combination maintenance therapies with an avelumab backbone, Aragon-Ching says. When evaluating new regimens in the first-line maintenance setting, avelumab should be the standard-of-care treatment used for comparison, Aragon-Ching concludes.